Pharmaceuticals, Biotechnology and Life Sciences
PARIS–(BUSINESS WIRE)–Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D.,…
Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.
Pacific Biosciences’ Single Molecule, Real-Time Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic diseases. As part of this work, scientists will sequence more than 500 whole human genomes with the PacBio Sequel II System to pinpoint disease-causing variants.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Allergan got U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
Bayer named Marianne De Backer PhD as the new Head of Business Development & Licensing of its Pharmaceuticals Division. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company’s Pharmaceuticals Division and join the Pharmaceuticals Executive Committee with immediate effect.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications.
A new forensic authentication feature for pharmaceutical labels is offered by Schreiner MediPharm in cooperation with Applied DNA Sciences: SigNature® DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect their products against counterfeiting and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe,…
AstraZeneca Tagrisso in a phase 3 trial, with previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, brought positive overall survival (OS) results.